ChemoCentryx Inc (CCXI) was Initiated by JMP Securities to “Mkt Outperform”. JMP Securities advised their Clients and Investors in a research report released on Feb 21, 2017.
Several company insiders have filed Insider transactions , on Feb 3, 2017, Roger C Lucas (director) sold 4,000 shares at $7.32 per share price. According to the SEC, on Jan 4, 2017, Markus J. Cappel (Chief Bus. Officer & Treasurer) sold 26,821 shares at $7.51 per share price. On Dec 7, 2016, Petrus Bekker (Chief Medical Officer) sold 30,000 shares at $8.50 per share price, according to the Form-4 filing with the securities and exchange commission.
ChemoCentryx Inc opened for trading at $6.82 and hit $7.21 on the upside on Friday, eventually ending the session at $7.04, with a gain of 3.07% or 0.21 points. The heightened volatility saw the trading volume jump to 1,28,773 shares. Company has a market cap of $337 M.
ChemoCentryx Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer. It targets the chemoattractant system which is a network of molecules including chemokine ligands and their associated receptors as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company’s product portfolio includes CCX140 CCX872 CCX168 Vercirnon (Traficet-EN or CCX282) and CCX507.